Asthma Research Today is a free monthly online journal that collates and summarizes the latest research about Asthma, including details on symptoms, diagnosis, treatment, causes, medications.

A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma.

Caceres AI, Brackmann M, Elia MD, Bessac BF, del Camino D, D'Amours M, Witek JS, Fanger CM, Chong JA, Hayward NJ, Homer RJ, Cohn L, Huang X, Moran MM, Jordt SE

Department of Pharmacology, Yale University School of Medicine, 333 Cedar St., New Haven, CT 06520, USA.

Asthma is an inflammatory disorder caused by airway exposures to allergens and chemical irritants. Studies focusing on immune, smooth muscle, and airway epithelial function revealed many aspects of the disease mechanism of asthma. However, the limited efficacies of immune-directed therapies suggest the involvement of additional mechanisms in asthmatic airway inflammation. TRPA1 is an irritant-sensing ion channel expressed in airway chemosensory nerves. TRPA1-activating stimuli such as cigarette smoke, chlorine, aldehydes, and scents are among the most prevalent triggers of asthma. Endogenous TRPA1 agonists, including reactive oxygen species and lipid peroxidation products, are potent drivers of allergen-induced airway inflammation in asthma. Here, we examined the role of TRPA1 in allergic asthma in the murine ovalbumin model. Strikingly, genetic ablation of TRPA1 inhibited allergen-induced leukocyte infiltration in the airways, reduced cytokine and mucus production, and almost completely abolished airway hyperreactivity to contractile stimuli. This phenotype is recapitulated by treatment of wild-type mice with HC-030031, a TRPA1 antagonist. HC-030031, when administered during airway allergen challenge, inhibited eosinophil infiltration and prevented the development of airway hyperreactivity. Trpa1(-/-) mice displayed deficiencies in chemically and allergen-induced neuropeptide release in the airways, providing a potential explanation for the impaired inflammatory response. Our data suggest that TRPA1 is a key integrator of interactions between the immune and nervous systems in the airways, driving asthmatic airway inflammation following inhaled allergen challenge. TRPA1 may represent a promising pharmacological target for the treatment of asthma and other allergic inflammatory conditions.

Published 5 June 2009 in Proc Natl Acad Sci U S A, 106(22): 9099-104.
Full-text of this article is available online (may require subscription).

Articles on Asthma published 2 June 2009:

Quality improvement strategies for children with asthma: a systematic review.   Arch Pediatr Adolesc Med, 163(6): 572-81.

OBJECTIVE: To evaluate the evidence that quality improvement (QI) strategies can improve the processes and outcomes of outpatient pediatric asthma care. DATA SOURCES: Cochrane Effective Practice and Organisation of Care Group database (January 1966 to April 2006), MEDLINE (January 1966 to April 2006), Cochrane Consumers and Communication Group database (January 1966 to May 2006), and bibliographies of retrieved articles. STUDY SELECTION: Randomized controlled trials, controlled before-after ... [Abstract] [Full-text]

Articles on Asthma published 1 June 2009:

Effects of multi-walled carbon nanotubes on a murine allergic airway inflammation model.   Toxicol Appl Pharmacol, 237(3): 306-16.

The development of nanotechnology has increased the risk of exposure to types of particles other than combustion-derived particles in the environment, namely, industrial nanomaterials. On the other hand, patients with bronchial asthma are sensitive to inhaled substances including particulate matters. This study examined the effects of pulmonary exposure to a type of nano-sized carbon nanotube (multi-walled nanotubes: MWCNT) on allergic airway inflammation in vivo and their cellular mechanisms ... [Abstract] [Full-text]

Articles on Asthma published 21 May 2009:

African ancestry is associated with risk of asthma and high total serum IgE in a population from the Caribbean Coast of Colombia.   Hum Genet, 125(5): 565-79.

African descended populations exhibit an increased prevalence of asthma and allergies compared to Europeans. One approach to distinguish between environmental and genetic explanations for this difference is to study relationships of asthma risk to individual admixture. We aimed to determine the admixture proportions of a case-control sample from the Caribbean Coast of Colombia currently participating in genetic studies for asthma, and to test for population stratification and association ... [Abstract] [Full-text]

Articles on Asthma published 15 May 2009:

Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene.   Am J Hum Genet, 84(5): 581-93.

Asthma, a chronic airway disease with known heritability, affects more than 300 million people around the world. A genome-wide association (GWA) study of asthma with 359 cases from the Childhood Asthma Management Program (CAMP) and 846 genetically matched controls from the Illumina ICONdb public resource was performed. The strongest region of association seen was on chromosome 5q12 in PDE4D. The phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila) gene (PDE4D) is ... [Abstract] [Full-text]

Articles on Asthma published 14 May 2009:

Is the association between low birth weight and asthma independent of genetic and shared environmental factors?   Am J Epidemiol, 169(11): 1337-43.

Epidemiologic evidence linking birth weight and asthma is inconsistent. The authors examined the association between birth weight and asthma during childhood and adult life in twins. Using prospectively collected data on 21,588 like-sexed Swedish twins of known zygosity born in 1928-1952, they first conducted a cohort study to examine the risk of asthma in relation to birth weight. Next, they conducted nested co-twin control analyses among 643 dizygotic and 365 monozygotic twin pairs discordant ... [Abstract] [Full-text]

Articles on Asthma published 11 May 2009:

Oropharyngeal aspiration: an alternative route for challenging in a mouse model of chemical-induced asthma.   Toxicology, 259(1): 84-9.

BACKGROUND: To assess the importance of the route of challenge in an existing mouse model of chemical-induced asthma, we replaced intranasal instillation by oropharyngeal aspiration. To our knowledge, oropharyngeal aspiration as a challenge route has not yet been investigated in a mouse model of chemical-induced asthma. METHODS: On days 1 and 8, mice were dermally sensitized with toluene diisocyanate (TDI) (0.3%) [or vehicle (acetone/olive oil)] and on day 15 they received a single challenge, ... [Abstract] [Full-text]

Articles on Asthma published 5 May 2009:

Inadequate documentation of asthma management in hospitalized adult patients.   South Med J, 102(5): 510-4.

Undocumented patient information in the medical record (MR) is a barrier to providing high quality care. Inadequate documentation has recently been reported for two cardiovascular diseases. This study was designed to evaluate the documentation of asthma management in the MR to determine if it is consistent with the NIH asthma guidelines. We performed a retrospective chart review of patients (ages 18-49) admitted to the hospital with an ICD-9 code for a primary diagnosis of asthma between ... [Abstract] [Full-text]

Articles on Asthma published 4 May 2009:

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol.   J Allergy Clin Immunol, 123(5): 1083-9, 1089.e1-7.

BACKGROUND: Budesonide/formoterol maintenance and reliever therapy maintains asthma control and reduces exacerbation frequency compared with higher fixed-dose combination regimens. Its effects on eosinophilic airway inflammation and structure are unknown. OBJECTIVE: We sought to compare the effects of budesonide/formoterol 200/6 microg twice daily plus as-needed with budesonide/formoterol 800/12 microg twice daily on airway eosinophils and remodeling. METHODS: This 52-week, parallel-group, ... [Abstract] [Full-text]

© 2004-2009 Asthma Research Today. All Rights Reserved.